Comparison of tadalafil monotherapy and its combination with mirabegron for efficacy in the treatment of storage symptoms with benign prostatic hyperplasia
Latest Information Update: 21 Aug 2020
Price :
$35 *
At a glance
- Drugs Mirabegron (Primary) ; Tadalafil (Primary)
- Indications Benign prostatic hyperplasia; Overactive bladder
- Focus Therapeutic Use
- 26 Jul 2020 Results presented at the 35th Congress of the European Association of Urology
- 06 Sep 2019 Status changed from recruiting to completed.
- 29 Dec 2017 New trial record